Myriad Genetics is a leading biopharmaceutical company focused on the development of novel healthcare products. The Companys lead drug candidate, Flurizan, is currently accepting enrollment for two Phase 3 clinical trials in Alzheimers disease. Myriad has a full pipeline of preclinical drug candidates in development including two Phase I human clinical trials for cancer drugs, Azixa and MPC-2130. The Company markets molecular diagnostic tests to determine the risk of breast cancer, ovarian cancer, colon cancer, endometrial cancer and melanoma skin cancer in individuals with a family history of cancer.